BSERose Merc LtdHighNeutral
Announced Tue, 24 Mar · 20:46 IST

As per the annexure enclosed.

Fund Raising View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.9%1-day move
₹69.00
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.9+1.1+1.4+1.3+6.8+2.4-1.8-7.2-8.6-10.1
Up moveDown movePending
AI summary

Rose Merc's board approved the allotment of 3,55,723 convertible warrants at Rs. 90 each (Rs. 80 premium) to 13 allottees — 1 promoter and 12 non-promoters — on a preferential basis, with total potential consideration of about Rs. 3.20 crore. The company has already received Rs. 80.04 lakh as the 25% upfront payment, with the balance 75% due upon conversion within 18 months. The board also accepted the resignation of a director from subsidiary Rahi Pakhle RM Private Limited, reclassifying it as an associate, and approved the sale of a 49% stake in Kaale and Rose Merc Advisors for Rs. 49,000, which similarly shifts to associate status. Additionally, the company completed a 48% acquisition in Abaca Care Private Limited (organic homeopathy healthcare) for Rs. 48,000, making it a new subsidiary, and appointed Vikas Phadnis as Advisor – Strategy and Growth.

Likely market impact

The preferential warrant issue is a small fundraising exercise (under Rs. 3.5 crore) that could dilute equity once converted over the next 18 months. The restructuring is minor, with negligible financial impact given the tiny revenue and net worth of the entities involved. The healthcare acquisition and the high-profile advisor appointment signal a strategic pivot, though deal sizes are symbolic — overall impact on share price is likely to be limited.